Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Gains from Sales and Divestitures (2020 - 2024)

Aligos Therapeutics filings provide 4 years of Gains from Sales and Divestitures readings, the most recent being $4874.0 for Q3 2024.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $4874.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $4874.0, a N/A change, with the full-year FY2022 number at $89054.0, down 72.11% from a year prior.
  • Gains from Sales and Divestitures hit $4874.0 in Q3 2024 for Aligos Therapeutics, up from $2490.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $418776.0 in Q4 2020 to a low of $2490.0 in Q1 2024.
  • Median Gains from Sales and Divestitures over the past 4 years was $89054.0 (2022), compared with a mean of $134929.4.
  • Biggest five-year swings in Gains from Sales and Divestitures: decreased 23.74% in 2021 and later plummeted 72.11% in 2022.
  • Aligos Therapeutics' Gains from Sales and Divestitures stood at $418776.0 in 2020, then dropped by 23.74% to $319357.0 in 2021, then plummeted by 72.11% to $89054.0 in 2022, then crashed by 94.53% to $4874.0 in 2024.
  • The last three reported values for Gains from Sales and Divestitures were $4874.0 (Q3 2024), $2490.0 (Q2 2024), and $2490.0 (Q1 2024) per Business Quant data.